Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04411914 · ClinicalTrials.gov registry record · Phase 1

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

A Phase 1 study, sponsored by Temple University.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target

NCT04411914: Completed Phase 1 study, sponsored by Temple University.

NCT04411914 is a Phase 1 study that has completed, run by Temple University. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04411914, a Phase 1 study, has completed, sponsored by Temple University.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target

Study Summary

A dose-escalation study to determine the optimum dose of Clavulanic Acid (CLAV) for effects on craving and efficacy.

Primary Outcome

Brain glutamate concentration in the ACC (based on Magnetic Resonance Spectroscopy (MRS)) will be correlated with cocaine craving (measured by Cocaine Craving Questionnaire (CCQ)) in subjects receiving escalating doses of CLAV for 10 days. Measurement will be made at baseline and Day 10 of CLAV (1000 mg/day) in subjects with cocaine use disorder.

Interventions

  • OTHER Placebo
  • DRUG Clavulanic Acid

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2020-09-01
Est. Completion 2022-03-31
Phase Phase 1
Temple University

163 total trials

What the finished NCT04411914 record still lists

NCT04411914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04411914 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04411914 about?

NCT04411914 is a clinical study titled "Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid". A dose-escalation study to determine the optimum dose of Clavulanic Acid (CLAV) for effects on craving and efficacy.

What is the current status of trial NCT04411914?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-09-01. Estimated completion is 2022-03-31.

What interventions are being tested in trial NCT04411914?

The interventions under investigation include: Placebo (OTHER), Clavulanic Acid (DRUG).

Who is sponsoring clinical trial NCT04411914?

This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04411914's enrollment target sits among peer trials

13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04411914, the US trial registry maintained by the National Library of Medicine. NCT04411914 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.